
Whatever Johnson & Johnson ($JNJ) learned about MacroGenics’ off-the-shelf approach to stirring a T cell attack against cancer since inking their first partnership deal 17 months ago seems to have only whetted the pharma giant’s appetite for more.

Whatever Johnson & Johnson ($JNJ) learned about MacroGenics’ off-the-shelf approach to stirring a T cell attack against cancer since inking their first partnership deal 17 months ago seems to have only whetted the pharma giant’s appetite for more.

Novartis is splitting its pharmaceuticals division into two business units, one focused on cancer and the second on other drugs, while switching out its current pharma head in the second high-profile management reshuffle this year.

Dr. J. Thomas August, who has spent the last 40 years at Johns Hopkins and decades developing a way for people to fight off viruses, has turned his attention to developing a Zika virus vaccine. He is relying upon one of his own discoveries – a means of delivering cells injected with the DNA code of the virus to a person’s own immune system to fight off infection. “Others talk about 10 years to invent and develop a new vaccine,” said August, “We’re going to do this in about a year.” August is bankrolling his new Baltimore-based company called Pharos Biologicals with his own money and has enlisted CEO David Wise to help raise as much as $5 million to conduct the initial trials.

The TMCx accelerator program couples the resources of Texas Medical Center with the innovative horsepower of entrepreneurs working in the areas of medical technology and digital health. Throughout the program, startups engage with TMC physicians and other hospital stakeholders to refine their value proposition and determine their product/market fit.
![]()
Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, today announced that it has entered into a definitive agreement to sell 2,700,000 shares of its common stock and warrants to purchase 2,700,000 shares of common stock in a private placement. The securities are being sold in a private offering at a price of $0.40 per one share of common stock and one common stock purchase warrant. The warrants have an exercise price of $0.40 per share, are immediately exercisable and expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants are immediately separable and will be issued separately.
![]()
Researchers at the University of Maryland were able pull away color and chemicals from a block of wood to leave it impressively see-through. The result is a material that is both stronger and more insulating than glass, with better biodegradability than plastic. “We were very surprised by how transparent it could go,” said Liangbing Hu, who wrote about the project in Advanced Materials.

At the North Bethesda Marriott, Maryland’s leading technology and life science companies gathered to celebrate recent successes from the most innovative teams in the state on Thursday night’s industry celebration.

Sanofi Genzyme, the specialty care global business unit of Sanofi (NYSE: SNY), announced today a research collaboration with the Johns Hopkins School of Medicine that will focus on novel strategies aimed at advancing the understanding of underlying causes of disease progression in multiple sclerosis (MS). The collaboration, under guidance by a joint committee of representatives from Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Center, will leverage certain technologies and methodologies designed to inform new therapeutic approaches to treating disease progression.

Satellite campuses are increasingly popular for public institutions hoping to expand their reach and increase access to students throughout the state, but the Post reports Maryland’s configuration of combining nine satellite programs onto one campus is unique.

The 2030 Group has hired a consultant to create a campaign to rebrand Greater Washington and expects to launch that campaign early next year. The fear is that the region all too often loses its best and brightest to places such as Silicon Valley and lags when it comes to diversifying its economy away from a dependence on the federal government to a more entrepreneurial one centered on innovation.